Close Menu

NEW YORK (GenomeWeb) – Transgenomic today announced that it has amended its license agreement with Exiqon to include the rights to Exiqon's locked nucleic acid (LNA) oligonucleotides.

The new agreement provides Transgenomic with access to LNA oligos for use with all of its mutation enrichment technologies, including multiplexed ICE COLD-PCR. It also covers worldwide commercial use of LNA oligos for analysis of all cancer genes on all platforms, including next-generation sequencing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.

Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.

Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.

In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.